Q-omics provides the consensus-scored PKHD1L1 profile across patient tissues and cancer cell-line models. PKHD1L1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PKHD1L1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, PKHD1L1 RNA expression shows 15,952 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, COAD, and LSCC as cancer lineages where PKHD1L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKHD1L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKHD1L1 survival associations across molecular data types. PKHD1L1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKHD1L1 RNA expression–survival associations across cancer types. High PKHD1L1 expression shows unfavorable associations in KIRP and LGG, but favorable associations in SKCM, HNSC, LUAD and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PKHD1L1 RNA expression.
This table summarizes PKHD1L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PKHD1L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKHD1L1 shows lower tumor expression in COAD, HNSC, THCA, KIRC, LUAD and LUSC. The COAD box plot shows higher PKHD1L1 RNA expression in normal versus tumor tissue (log2 FC = −0.831, t-test p < 0.001).
This table shows molecular features associated with PKHD1L1 in patient tissues and cancer cell lines. In patient samples, PKHD1L1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PKHD1L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
